AU2004288654B2 - Vaccine and method for treatment of neurodegenerative diseases - Google Patents
Vaccine and method for treatment of neurodegenerative diseases Download PDFInfo
- Publication number
- AU2004288654B2 AU2004288654B2 AU2004288654A AU2004288654A AU2004288654B2 AU 2004288654 B2 AU2004288654 B2 AU 2004288654B2 AU 2004288654 A AU2004288654 A AU 2004288654A AU 2004288654 A AU2004288654 A AU 2004288654A AU 2004288654 B2 AU2004288654 B2 AU 2004288654B2
- Authority
- AU
- Australia
- Prior art keywords
- disease
- copolymer
- mice
- cells
- cop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51862703P | 2003-11-12 | 2003-11-12 | |
| US60/518,627 | 2003-11-12 | ||
| US61096604P | 2004-09-20 | 2004-09-20 | |
| US60/610,966 | 2004-09-20 | ||
| PCT/IL2004/001037 WO2005046719A1 (en) | 2003-11-12 | 2004-11-11 | Vaccine and method for treatment of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004288654A1 AU2004288654A1 (en) | 2005-05-26 |
| AU2004288654B2 true AU2004288654B2 (en) | 2009-12-03 |
Family
ID=34594916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004288654A Ceased AU2004288654B2 (en) | 2003-11-12 | 2004-11-11 | Vaccine and method for treatment of neurodegenerative diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20080085269A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1684797A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5456235B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004288654B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2546077C (cg-RX-API-DMAC7.html) |
| IL (2) | IL175535A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005046719A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| CA2546077C (en) | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| DK1701730T3 (da) * | 2003-12-09 | 2013-11-25 | Yeda Res & Dev | Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| WO2010019270A1 (en) * | 2008-08-14 | 2010-02-18 | Isis Pharmaceuticals, Inc. | Modulation of prion expression |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| WO2013059322A2 (en) * | 2011-10-17 | 2013-04-25 | Lawrence Steinman | Amyloid beta peptide as a therapy for inflammation |
| EP3027205A4 (en) | 2013-07-28 | 2017-07-19 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR20200029627A (ko) * | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| US11058720B2 (en) * | 2016-05-20 | 2021-07-13 | Cedars-Sinai Medical Center | Methods of treating or preventing alzheimer's disease and associated conditions |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| US12281305B2 (en) | 2018-11-21 | 2025-04-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing prion expression |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001052878A2 (en) * | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| WO2001093893A2 (en) * | 2000-06-07 | 2001-12-13 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US6071970A (en) * | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
| US6794414B1 (en) * | 1998-06-17 | 2004-09-21 | Yeda Research And Development Co. Ltd. | Method and compositions for treating diseases mediated by transglutaminase activity |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES |
| JP2003521448A (ja) | 1998-07-23 | 2003-07-15 | ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 合成ペプチドおよび自己免疫疾患治療のための使用方法 |
| IL148202A0 (en) * | 2000-06-20 | 2002-09-12 | Caprion Pharmaceuticals Inc | Copolymers and methods of treating prion-related diseases |
| ES2387082T3 (es) * | 2001-05-17 | 2012-09-13 | Merck Serono Sa | Uso de OSTEOPONTINA para el tratamiento y/o prevención de enfermedades neurológicas |
| US7718699B1 (en) * | 2005-03-04 | 2010-05-18 | Broyles Robert H | Abscissic acid and derivatives thereof for the treatment of diseases |
| US7351686B2 (en) | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| CA2546077C (en) | 2003-11-12 | 2016-07-05 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| US7220729B2 (en) * | 2004-05-10 | 2007-05-22 | Academia Sinica | Huntington's Disease Treatment |
-
2004
- 2004-11-11 CA CA2546077A patent/CA2546077C/en not_active Expired - Fee Related
- 2004-11-11 AU AU2004288654A patent/AU2004288654B2/en not_active Ceased
- 2004-11-11 US US10/578,899 patent/US20080085269A1/en not_active Abandoned
- 2004-11-11 JP JP2006539072A patent/JP5456235B2/ja not_active Expired - Fee Related
- 2004-11-11 WO PCT/IL2004/001037 patent/WO2005046719A1/en not_active Ceased
- 2004-11-11 EP EP04799345A patent/EP1684797A1/en not_active Withdrawn
- 2004-11-11 EP EP10012062.5A patent/EP2301569B1/en not_active Expired - Lifetime
-
2006
- 2006-05-10 IL IL175535A patent/IL175535A/en active IP Right Grant
-
2011
- 2011-04-29 US US13/097,427 patent/US8828404B2/en not_active Expired - Fee Related
-
2013
- 2013-01-24 IL IL224393A patent/IL224393B/en active IP Right Grant
-
2014
- 2014-01-23 US US14/162,482 patent/US9517256B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001052878A2 (en) * | 2000-01-20 | 2001-07-26 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| WO2001093893A2 (en) * | 2000-06-07 | 2001-12-13 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
Non-Patent Citations (4)
| Title |
|---|
| E.J. Benner Et Al. Abstract No. 440.1, Annual Meeting of the Society of Neuroscience, 08 November 2003 * |
| Kipnis, J. & M. Schwartz, Trends Mol Med, 2002, Vol. 8, No. 7, pp 319-323 * |
| Schwartz, M. & J. Kipnis, Drug Dev Research, 2002, Vol.56, no. 2, pp 143-149 * |
| Schwartz. M., Cell and Mol Neurobiol, 2001, Vol. 21, No. 6, pp 617-627 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110206706A1 (en) | 2011-08-25 |
| US20080085269A1 (en) | 2008-04-10 |
| JP2007513079A (ja) | 2007-05-24 |
| US20140134196A1 (en) | 2014-05-15 |
| CA2546077C (en) | 2016-07-05 |
| IL224393B (en) | 2018-06-28 |
| CA2546077A1 (en) | 2005-05-26 |
| US8828404B2 (en) | 2014-09-09 |
| IL175535A0 (en) | 2006-09-05 |
| EP1684797A1 (en) | 2006-08-02 |
| WO2005046719A1 (en) | 2005-05-26 |
| EP2301569A2 (en) | 2011-03-30 |
| US9517256B2 (en) | 2016-12-13 |
| IL175535A (en) | 2016-03-31 |
| EP2301569B1 (en) | 2018-05-02 |
| JP5456235B2 (ja) | 2014-03-26 |
| AU2004288654A1 (en) | 2005-05-26 |
| EP2301569A3 (en) | 2011-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9517256B2 (en) | Vaccine and method for treatment of neurodegenerative diseases | |
| AU2002345323B2 (en) | Use of poly-Glu, Tyr for neuroprotective therapy | |
| WO2001093893A2 (en) | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy | |
| EP2046366B1 (en) | Copolymer-1 for treatment of age-related macular degeneration | |
| AU2002353486B2 (en) | Vaccine and method for treatment of motor neurone diseases | |
| US7399740B2 (en) | Poly-Glu,Tyr for neuroprotective therapy | |
| US20090010873A1 (en) | Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis | |
| US20110117115A1 (en) | Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders | |
| US20040192588A1 (en) | Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration | |
| US20050220803A1 (en) | Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ | |
| AU2004297044B2 (en) | Method and vaccine comprising Copolymer 1 for treatment of psychiatric disorders | |
| IL176217A (en) | Pharmaceutical compositions comprising copolymer 1 for treatment of post-traumatic stress disorder (ptsd), schizophrenia, depression or bipolar disorder | |
| HK1127858B (en) | Copolymer-1 for treatment of age-related macular degeneration | |
| CA2296999A1 (en) | Activated t-cells and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |